Therapeutic results in treatment of Hodgkin's disease with CB 1348 and R-48.

The first clinical trial in malignant lynsphoma appeared in 1955.2 The authors found the drug to be definitely useful in follicular lymphoma and lymphocytic leukemia, and to some extent in Hodgkin’s disease. They concluded that it deserved further trial. This opinion was recently concurred in by a group of workers in this country3 who treated 24 patients. Our work with CB 1348 involved 31 patients with Hodgkin’s disease who were treated and kept under observation for a period of 31 months. Fifteen of the group were males and sixteen were females ; the age range was as follows : two aged 20 years, seven 21-30 years, ten 31-40 years, nine 41-50 years, two 51-60 years and one 64 years. Three patients of our group were persons in whons the disease had been discovered only two to three months previous to institution of CB 1348 therapy; seventeen others had had t-he disease one to three years; four had been diagnosed four to five years previously; seven from five to thirteen years previously. When therapy was begun thirteen patients were in good condition, seven fair, nine poor, and two were terminal. Two patients had had no previous therapy, one had had radical neck surgery only, 28 had previously received one or more of the following therapies: radiation, nitrogen mustard, tniethylenenselamine, But-azolidin, ACTH, cortisone, Meticorten. Treatment with the chcnsotherapeutic agent in question was instituted for control of symptoms such as pain, pruritus, malaise, fever, chills, loss of appetite, loss of weight, presence of palpable lymph nodes, enlargement of spleen. The following laboratory procedures were used as objective criteria for effec-